The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
Abstract
OBJECTIVE: This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia. METHOD: This randomized trial occurred at four North American clinics in the Prevention Through Risk Identification, Management, and Education project. Outpatients received olanzapine (5-15 mg/day, N=31) or placebo (N=29) during a 1-year double-blind treatment period and no treatment during a 1-year follow-up period. Efficacy measures included the conversion-to-psychosis rate and Scale of Prodromal Symptoms scores. RESULTS: During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experienced a conversion to psychosis, a nearly significant difference. The hazard of conversion among placebo patients was about 2.5 times that among olanzapine-treated patients, which also approached significance. In the follow-up year, the conversion rate did not differ significantly between groups. During treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixed-model repeated-measures least-squares mean score showed significantly greater improvement between weeks 8 and 28 with olanzapine. The olanzapine patients gained significantly more weight (mean=8.79 kg, SD=9.05, versus mean=0.30 kg, SD=4.24). CONCLUSIONS: A significant treatment difference in the conversion-to-psychosis rate was not demonstrated. However, these results may be influenced by low power. The nearly significant differences suggest that olanzapine might reduce the conversion rate and delay onset of psychosis. Olanzapine was efficacious for positive prodromal symptoms but induced weight gain. Further treatment research in this phase of illness is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, clinical trials have failed so far to provide clear evidence that antipsychotics can prevent conversion to schizophrenia in at-risk individuals 63 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Miller, T. J., McGlashan, T. H., Rosen, J. L., Cadenhead, K. S., Ventura, J., McFarlane, W. R., Perkins, D. O., Pearlson, G. D., & Woods, S. W. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007040 · Cited by 1,800
Self-citationMeasurement of Premorbid Adjustment in Chronic Schizophrenia
Cannon-Spoor, H. E., Potkin, S. G., & Wyatt, R. J. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.3.470 · Cited by 1,220
Global Assessment of Functioning
Hall, R. C. W. (1995) · Psychosomatics · doi:10.1016/s0033-3182(95)71666-8 · Cited by 1,099
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- McGlashan TH, 2001, Netherlands, Kluwer Academic, 135
- Guy, 1976, ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338
Cited by
Sorted by citations
Items 401–500 of 557
Early detection of schizophrenia
Klosterkötter, J. (2011) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2011.02.001 · Cited by 5
McGorry, P. D., Nelson, B., & Goldstone, S. D. (2012) · Clinical Practice · doi:10.2217/cpr.12.69 · Cited by 5
Assessment and treatment of the risk of psychosis in adolescents--a review.
Zdanowicz, N., Mees, L., Jacques, D., Tordeurs, D., & Reynaert, C. (2014) · PubMed · Cited by 5
Zhang, T., Xu, L., Li, H., Cui, H., Tang, Y., Wei, Y., Tang, X., Hu, Y., Hui, L., Li, C., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291721000064 · Cited by 5
Using research and evaluation to inform the development ofearly-psychosis service models
Harris, M., Craig, T., Zipursky, R. B., Addington, D. E., Nordentoft, M., & Power, P. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511576287.022 · Cited by 5
Self-citationPsychosis Risk Syndrome: What Now?
Sentissi, O., ANDREOU, M. A., Moeglin, C., Curtis, L., & BROSCH, M. S. (2017) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000272 · Cited by 5
At-risk mental state and prediction
Yung, A. R., Klosterkötter, J., Cornblatt, B. A., & Schultze‐Lutter, F. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511576287.007 · Cited by 5
Addington, J., & Lewis, S. W. (2010) · Wiley eBooks · doi:10.1002/9781444327298.ch6 · Cited by 4
Self-citationShould the diagnostic boundaries of schizophrenia be expanded?
David, A. S. (2011) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2011.554276 · Cited by 5
Psychotherapies for the Psychoses
Shyu, T. (2009) · Journal of Mental Health · doi:10.1080/09638230902946858 · Cited by 5
The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment
Dwivedi, J., Seemab, M., Wal, P., Dey, P., Rathinam, T., Dhamini, A., & Khan, A. (2025) · Current Drug Metabolism · doi:10.2174/0113892002382047250930160449 · Cited by 4
Lee, J., Barnett, P., Goldsmith, L. P., Yang, J., Appleton, R., Lloyd‐Evans, B., Hahn, J. S., Rich, N., Francis, E., Mitchell, L., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04617-1 · Cited by 4
Mental Health Retrosight: Final report on Phase I
Wooding, S., Keyser, D. J., Chonaill, S. N., Schultz, D. J., Pincus, H. A., Pollitt, A., Horvitz-Lennon, M. V., Yaqub, O., Morris, Z. S., & Grant, J. (2012) · Cited by 4
Wasserthal, S., Muthesius, A., Hurlemann, R., Ruhrmann, S., Schmidt, S. J., Hellmich, M., Schultze‐Lutter, F., Klosterkötter, J., Müller, H., Meyer‐Lindenberg, A., et al. (2024) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgae005 · Cited by 4
Very Early Interventions in Psychotic Disorders
Bhangoo, R. K., & Carter, C. S. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2008.10.003 · Cited by 4
The DSM‐IV version of schizophrenia may be harmful to patients' health
McGlashan, T. H. (2007) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2007.00048.x · Cited by 4
Self-citationTreatment of first-episode and prodromal signs
Singh, S. P., & Merino, C. (2008) · Psychiatry · doi:10.1016/j.mppsy.2008.10.001 · Cited by 4
Therapeutic Considerations in Individuals at Clinical Risk for Developing Psychosis
Singh, F., DeJoseph, M. L., & Cadenhead, K. S. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0009-2 · Cited by 4
How should we intervene in psychosis risk syndromes?
Wang, J., Jiang, K., Zhang, T., Li, H., Woodberry, K. A., & Seidman, L. J. (2013) · PubMed Central · doi:10.3969/j.issn.1002-0829.2013.01.003 · Cited by 4
The Impact of Early Intervention in Schizophrenia
Yung, A. R., Killackey, E. J., Nelson, B., & McGorry, P. D. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0913-8_16 · Cited by 4
Early detection and treatment of patients symptomatically at-risk for psychosis
Schultze‐Lutter, F., Ruhrmann, S., & Schimmelmann, B. K. E. (2012) · Cited by 4
Lambert, M., & Correll, C. U. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-4427-1 · Cited by 4
Pharmacology and Neuroscience of Antipsychotic Drugs
Waddington, J. L., O’Tuathaigh, C. M. P., & Remington, G. J. (2010) · doi:10.1002/9781444327298.ch23 · Cited by 4
Gopal, A. A., Cosgrove, L., & Bursztajn, H. J. (2010) · Accountability in Research · doi:10.1080/08989621.2010.511568 · Cited by 4
Molecular Genetics of Schizophrenia: Focus on Symptom Dimensions
Ritsner, M. S., & Susser, E. (2009) · Springer eBooks · doi:10.1007/978-90-481-2298-1_4 · Cited by 4
Martinotti, G., Piro, T., Ciraselli, N., Persico, L., Inserra, A., Pettorruso, M., Maina, G., & Ricci, V. (2026) · Brain Science · doi:10.3390/brainsci16010112 · Cited by 4
Atypical antipsychotic agents for the schizophrenia prodrome: Not a clear first choice
Kruszewski, S. P., & Paczynski, R. P. (2008) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2008-0422 · Cited by 3
The Necessity of Family Type Interventions During First - Episode Psychosis in Schizophrenia
Sandica, B. A. (2013) · Journal of Trauma & Treatment · doi:10.4172/2167-1222.1000e111 · Cited by 2
Greydanus, D. E., Azeem, M. W., & Nazeer, A. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.101983 · Cited by 3
Ribolsi, M., Nastro, F. F., Pelle, M., Esposto, E., Jannini, T. B., & Lorenzo, G. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155432 · Cited by 3
As artes adivinhatórias e a psiquiatria do futuro
HENRIQUES, R. P., & LEITE, A. F. S. (2017) · Fractal Revista de Psicologia · doi:10.22409/1984-0292/v29i1/1552 · Cited by 3
Psicoterapia de la Psicosis: De la Persona en Riesgo al Paciente Crónico
Díaz, N. E., Avezuela, N. R., Manuel, G. M., Carlos, F. F. J., & Ignacio, G. C. (2010) · Clínica y Salud · doi:10.5093/cl2010v21n3a6 · Cited by 3
Intervening in clinical research to prevent the onset of psychoses: conflicts and obligations
Lysaght, T., Capps, B., Campbell, A. V., Subramaniam, M., & Chong, S. (2011) · Journal of Medical Ethics · doi:10.1136/medethics-2011-100008 · Cited by 3
ACTUALIZACIÓN EN LA PREVENCIÓN DE LOS TRASTORNOS DEL ESPECTRO PSICÓTICO
Fonseca‐Pedrero, E., Inchausti, F., & Rioja, U. D. L. (2018) · Papeles del Psicólogo - Psychologist Papers · doi:10.23923/pap.psicol2018.2860 · Cited by 4
Mahmood, Z., Kelsven, S., Cadenhead, K. S., Wykoff, J., Reyes-Madrigal, F., de la Fuente‐Sandoval, C., & Twamley, E. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00951 · Cited by 3
Early Intervention in the Indian Context
Singh, S. P. (2015) · Springer eBooks · doi:10.1007/978-81-322-1674-2_7 · Cited by 3
Prediction of Psychosis Through the Prodromal Syndrome
Cannon, T. D. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0913-8_13 · Cited by 3
Schizophrenia Biomarkers: A Means to Advance Disease Understanding, Diagnosis and Treatment
Schwarz, E., & Bahn, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_4 · Cited by 3
Miyamoto, S., Merrill, D. B., Jarskog, L. F., Fleishhacker, W. W., Marder, S. R., & Lieberman, J. A. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch104 · Cited by 4
Psychiatric Taxonomy, Psychopharmacology and Big Pharma
Cosgrove, L. (2010) · PsycEXTRA Dataset · doi:10.1037/e625812012-019 · Cited by 3
Hou, Y., Qiu, G., Xia, H., He, T., Liu, X., & Chen, A. (2024) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2024.100437 · Cited by 2
Raballo, A., Poletti, M., Lavalle, R., & Preti, A. (2026) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2026.03.014 · Cited by 2
Psychoseprävention jetzt in die klinische Versorgung einführen!
Bechdolf, A. (2013) · Psychiatrische Praxis · doi:10.1055/s-0032-1327393 · Cited by 2
Shapiro, D. I., Woodberry, K. A., Li, H., & Seidman, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_3 · Cited by 2
Zhu, H., Ning, Y., Zheng, S., Feng, S., Dong, L., & Jia, H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1160452 · Cited by 2
Phillips, L., Addington, J., & Morrison, A. P. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511576287.008 · Cited by 2
Self-citationBrain Protection in Neuropsychiatric Disorders: Past, Present and Future Challenges
Susser, E., & Ritsner, M. S. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_1 · Cited by 2
Guthrie, S., Wooding, S., Pollitt, A., Pincus, H. A., & Grant, J. (2013) · Cited by 2
Prescriptions d'antipsychotiques chez l'enfant et l'adolescent
Bonnot, O., Consoli, A., & Cohen, D. (2011) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(11)53146-3 · Cited by 2
Is Prevention a Realistic Goal for Schizophrenia?
Kohler, C. G., Borgmann‐Winter, K. E., Hurford, I. M., Neustadter, E. S., Yi, J. J., & Calkins, M. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0439-y · Cited by 2
Current approaches to the management of schizophrenia
Behan, C. L. (2009) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700000586 · Cited by 2
Bilgrami, Z. R., Kostek, N. T., Kim, I. T., Kraut, R., Kim, J. K., & Corcoran, C. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-19847-3_14 · Cited by 2
Chapter 4. Personality Disorders
Silk, K. R., & Jibson, M. D. (2010) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378074.lg04 · Cited by 2
Lambert, M., & Correll, C. U. (2016) · Der Nervenarzt · doi:10.1007/s00115-015-0055-z · Cited by 2
Alderman, T., & Domingues, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_12 · Cited by 1
Zheng, W., Xu, L., Zhang, D. H., Su, W., Wei, Y., Cui, H., Hong, Y., Zhao, J., Tang, X., Qian, Z., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf111 · Cited by 1
Solmi, M., Correll, C. U., Boldrini, T., Addington, J., Barbezat, E., Bassetto, S. A., Bechdolf, A., Devoe, D. J. A., Firth, J., Fusar‐Poli, P., et al. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2651738 · Cited by 1
Self-citationHealth Related Quality of Life in Subjects at Risk for a First Episode Of Psychosis
Bechdolf, A., Veith, V., Pukrop, R., & Klosterkötter, J. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5779-3_9 · Cited by 1
Delusions of body image in the prodrome
Smith, A. K., & Mittal, V. A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.033 · Cited by 1
Approche préventive dans la schizophrénie
Llorca, P., & Denizot, H. (2008) · Therapies · doi:10.2515/therapie:2008032 · Cited by 1
From genes to mental representations: a comment to "why schizophrenia genetics needs epigenetics".
Gaebel, W., & Zielasek, J. (2012) · PubMed · Cited by 1
Can we prevent the onset of psychosis? Yes, we can
Bechdolf, A., & Müller, H. (2012) · Neuropsychiatry · doi:10.2217/npy.12.19 · Cited by 1
Early intervention in the prodrome of psychosis
Holt, C., Butler, S., & Agius, M. (2011) · Cutting Edge Psychiatry in Practice · doi:10.65031/sxyb9245 · Cited by 1
Psychosis risk syndrome: is it worth the risk?
Yoon, C.-H., Agius, M. A., & Zaman, R. (2012) · PubMed · Cited by 1
Nonpharmalogical Substances for Early Intervention
Conus, P. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440922 · Cited by 1
Prävention von Psychosen: Erwartungen erfüllt
Bechdolf, A., & Peukert, R. (2011) · Psychiatrische Praxis · doi:10.1055/s-0030-1266056 · Cited by 1
Miller, B. J., & Buckley, P. F. (2009) · Medical psychiatry · doi:10.3109/9781420080063.017 · Cited by 1
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_11 · Cited by 1
Benvegnu, G., Letamendia, C. F. D. M., Vignes, M., & Raynaud, J. (2017) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2017.10.001 · Cited by 1
Früherkennung und Frühbehandlung von Menschen mit erhöhtem Psychoserisiko
Müller, H., & Bechdolf, A. (2020) · Springer eBooks · doi:10.1007/978-3-662-45995-9_26-1 · Cited by 1
The Role of Psychopharmacology in Mental Health Prevention
Lemon, C., & Thompson, A. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-97906-5_3 · Cited by 1
Schultze‐Lutter, F., Banaschewski, T., Barth, G. M., Bechdolf, A., Bender, S., Flechtner, H., Hackler, S., Heuer, F. H., Hohmann, S., Holzner, L., et al. (2024) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000981 · Cited by 1
Compton, M. T., Koplan, C. R., Oleskey, C., Powers, R. A., Pruitt, D. B., & Wissow, L. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378029.lg01 · Cited by 2
This Issue: Early Intervention for Psychotic Disorders
Compton, M. T. (2008) · Psychiatric Annals · doi:10.3928/00485713-20080801-05 · Cited by 1
A Brief Guide to Medications for Psychosis
Harris, A. W. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815012-2.00023-7 · Cited by 1
Neurobiology of Childhood-Onset Schizophrenia
Biswas, P. (2008) · Journal of Indian Association for Child and Adolescent Mental Health · doi:10.1177/0973134220080302 · Cited by 1
Indicated prevention in psychosis risk—psychological approaches
Addington, J., Piškulić, D., Devoe, D. J. A., Santesteban‐Echarri, O., & Stowkowy, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813201-2.00018-1 · Cited by 1
Self-citationPharmacological intervention for people at risk of psychotic disorder
Burkhardt, E., Leopold, K., & Bechdolf, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813201-2.00019-3 · Cited by 1
Gupta, T., Damme, K. S. F., Osborne, K. J., Vargas, T., Ristanovic, I., Frosch, I. R., Zarubin, V. C., Hitczenko, K., Williams, T. F., Cowan, H. R., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00089-3 · Cited by 1
Studying biomarkers in populations at genetic and clinical high risk for psychosis
de Koning, M. B. (2013) · doi:10.26481/dis.20131129mk · Cited by 1
Early Recognition and Prevention of Schizophrenia
McGorry, P. D., & Goldstone, S. D. (2011) · Wiley eBooks · doi:10.1002/9780470978672.ch5 · Cited by 1
Cognitive processing associated with hallucinations for At Risk Mental State
Leicester, S. (2013) · Minerva Access (University of Melbourne) · Cited by 1
Why transition is not the whole story: neurocognitive function and risk for psychosis
Lin, A. P. (2010) · Minerva Access (University of Melbourne) · Cited by 1
Sorter, M. T., & Vogel, D. A. (2012) · Wiley eBooks · doi:10.1002/9781119962229.ch24 · Cited by 1
Johnson, C. (2013) · Research Explorer (The University of Manchester) · Cited by 1
Studies of the affective and developmental domains of psychopathology in psychosis
Kaymaz, N. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20110622nk
Clients' and carers' experiences of an Early Intervention for Psychosis Service
Woolley, J. (2012) · ORCA Online Research @Cardiff (Cardiff University)
CBT for Individuals at High Risk of Developing Psychosis
Smethurst, N., French, P., & Morrison, A. P. (2012) · doi:10.1002/9781118330029.ch4
Velthorst, E. (2011) · UvA-DARE (University of Amsterdam)
Long-Chain Omega-3 Fatty Acids and Psychotic Disorders
Mossaheb, N., Schloegelhofer, M., Schaefer, M. R., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G. E., & Amminger, G. P. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-215-5_9
Cognitieve gedragstherapie bij jongeren met risicosymptomen voor een psychose
Nieman, D. H., Becker, H. E., Gevers, C., & LINSZEN, D. H. (2007) · Kind & Adolescent Praktijk · doi:10.1007/bf03059619
Preventive Interventions for Schizophrenia: A Case Report
Tahir, M. (2009) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.3.2.7
Ahn, Y. M., Choi, H. J., Han, J. W., Jang, S. J., Lyoo, I. K., & Kwon, J. S. (2013) · 신경정신의학 · doi:10.4306/jknpa.2013.52.1.17
Does Olanzapine Have Any Antidepressant Effect?
Moreira‐Almeida, A., & Pietrobon, R. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1838b
The Application of the Cognitive Behavioral Therapy in Schizophrenia
Lee, D.-E. (2012) · 신경정신의학 · doi:10.4306/jknpa.2012.51.6.359
Prodrom fiizofreni, Güncel Geliflmeler ve Sorunlar
Emül, M. (2006)
Linszen, D. H., Buitelaar, J. K., & Abdelmalik, N. (2008) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6632-3_17
The Thorns sextuplets. 1. The three who lived: Julie, Susan and Roger.
Watts, J. (1969) · PubMed
McGLASHAN, T. H. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1838a
Self-citationMcFarlane, W. R., Susser, E., Verdi, M., & McKeague, W. (2014)
Metadata
- Authors
- McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., Addington, D., Lindborg, S., Trzaskoma, Q., Tohen, M., & Breier, A.
- Affiliations
- Yale University (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2006-05
- Volume
- 163
- Issue
- 5
- Pages
- 790-799
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2121366540
- Cited by
- 556
- References
- 30
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 7 · 2022: 6 · 2021: 18 · 2020: 21 · 2019: 18 · 2018: 10 · 2017: 12 · 2016: 31 · 2015: 26 · 2014: 28 · 2013: 38 · 2012: 47
- FWCI
- 32.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Funders
- Eli Lilly and Company
- University of Toronto
- National Institutes of Health (5r24mh054446-05)
- National Institute of Mental Health (K05 MH-01654, MH01654, 1 K23 MH01905, K23MH001905, R01MH067073, R01 MH-67073, R24-MH-54446, R02 MH-50557, K05MH001654)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- olanzapine, transition to psychosis, weight gain, atypical antipsychotics
- MeSH terms
- Olanzapine, Adolescent, Ambulatory Care, Benzodiazepines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Obesity, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Severity of Illness Index, Antipsychotic Agents, Weight Gain, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
